Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:45 a.m. PT.
馬薩諸塞州沃爾瑟姆，2025年1月6日（全球貨幣新聞）—— Apellis Pharmaceuticals, Inc.（納斯達克：APLS）今天宣佈， 公司將於2025年1月13日星期一上午9:45在第43屆J.P.摩根醫療保健大會上進行演講。
The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 90 days following the event.
現場會議的網絡直播將在公司網站的「投資者與媒體」部分的「活動與演示」頁面上發佈。活動結束後，網絡直播的回放將在大約90天內提供。
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.
關於Apellis
Apellis Pharmaceuticals, Inc.是一家全球生物製藥公司，結合勇敢的科學與同情心，爲患者所面臨的某些最具挑戰性的疾病開發改變生命的療法。我們引入了15年來首個新類別的補體藥物，目前已有兩種針對C3的獲批藥物。這些藥物包括全球失明主要原因——地理性萎縮的首個治療方案。我們相信，我們才剛剛開始解鎖針對C3在嚴重眼底疾病、罕見病和神經疾病中的潛力。欲了解更多信息，請訪問或在Twitter和LinkedIn上關注我們。
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
投資者聯繫：
梅雷迪思·卡亞
meredith.kaya@apellis.com
617.599.8178
